ReviewCardiovascular research2025
Cardiac ageing: from hallmarks to therapeutic opportunities.
Review in Cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- From aging biology to cardiac biotechnology: emerging platforms for modeling cardiac aging.JCI insight · 2026Review
- Article
- Right heart function matters: prognostic value of sPAP, TAPSE and RV-PA coupling in a real-world cohort of TAVI patients.Cardiovascular intervention and therapeutics · 2026Article
- Seismocardiography for nonexercise estimation of cardiorespiratory fitness in older adults.BMC geriatrics · 2026Article
- Inflammation, metabolism, and aging in heart failure with preserved ejection fraction: Mechanisms and treatment perspectives.Journal of translational internal medicine · 2026Article
- Multi-region proteomic mapping identifies FTL1 and SERPINA3K as protective factors in cardiac aging.Cell death & disease · 2026Article
- Global Burden of Alcoholic Cardiomyopathy in Adults Aged 60 and Older From 1990 to 2021: A Secondary Analysis of Global Burden of Disease 2021 Data.Health science reports · 2026Article
- Therapeutic perspective on cardiomyopathy and heart failure in older adults through the lens of chronic inflammation.Vascular pharmacology · 2026Article
- Cardiac-related symptoms in individuals aged ≥65 years without diagnosed cardiac disease: insights from the NORSCREEN trial.European heart journal open · 2026Article
- SASP-mediated cellular senescence following myocardial infarction: from spatiotemporal immune regulation to therapeutic strategies.Frontiers in immunology · 2026Review
- Construction and evaluation of risk prediction model for major adverse cardiovascular events in peritoneal dialysis patients.Frontiers in nephrology · 2026Article
- Role of Vascular Niche in Cardiac Aging.Circulation research · 2025Article
- Long-term dietary allyl isothiocyanate, a TRPA1 agonist, ameliorates cardiac fibrosis and diastolic dysfunction in aged mice.GeroScience · 2025Article
- Article
- Exercise-Induced Cardiac Lymphatic Remodeling Mitigates Inflammation in the Aging Heart.Aging cell · 2025Article
- Anti-senescence therapies: a new concept to address cardiovascular disease.Cardiovascular research · 2025Review
- Is Senolytic Therapy in Cardiovascular Diseases Ready for Translation to Clinics?Biomolecules · 2025Review
- Circadian biology of cardiac aging.Journal of molecular and cellular cardiology · 2025Review
- Inflammation-Driven Prognosis in Advanced Heart Failure: A Machine Learning-Based Risk Prediction Model for One-Year Mortality.Journal of inflammation research · 2025Article
- Impact of plant-derived antioxidants on heart aging: a mechanistic outlook.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cardiac ageing is an intricate and multifaceted process with considerable impact on public health, especially given the global demographic shift towards aged populations. This review discusses structural, cellular, and functional changes associated with cardiac ageing and heart failure with preserved ejection fraction (HFpEF). Key molecular mediators are considered within the framework of the established hallmarks of ageing, with particular attention to promising therapeutic candidates. We further delineate the differential impacts of ageing on cardiac structure and function in men and women, addressing hormonal and chromosomal influences. The protective and mitigating effects of exercise in cardiac ageing and HFpEF in particular are discussed, as an inspiration for the identification of pathways that mitigate biological ageing. We also emphasize how much remains to be learned and the importance of these efforts in enhancing the cardiac health of ageing populations worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.